A Goldman Sachs star analyst known for pressing big pharma to break up is leaving the bank
- Jami Rubin, Goldman Sachs' lead pharmaceutical analyst, is leaving the bank.
- Rubin had been at Goldman Sachs since 2008.
- Rubin said in an email seen by Business Insider that she's becoming a banker and strategic advisor.
Goldman Sachs' top pharmaceutical analyst is leaving the bank.
Jami Rubin said in an email obtained by Business Insider that she's planning to become a banker and strategic advisor.
A spokeswoman from Goldman Sachs confirmed the contents of the email.
Rubin's been an analyst since the early 1990s and has famously pressed major pharmaceutical companies on their merger and acquisition plans. She joined Goldman Sachs in 2008 after working at Morgan Stanley and became a partner in 2012.
At Goldman Sachs, she's covered companies including Pfizer, Merck, Bristol-Myers, Johnson & Johnson and Allergan. For years, she repeatedly asked Pfizer about its plan to break up and spin off some of its businesses, a refrain that's carried over into other massive pharmaceutical companies. In 2016, Fortune called Rubin the "Conglomerate Killer."
"I am going to miss playing the "activist" analyst and asking tough questions," Rubin said in the email.